AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
MENLO PARK, Calif., April 05, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced participation in the 15th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 12:50 p.m. ET (9:50 a.m. PT) on Tuesday, April 12, 2016, in New York City. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
In addition to SEC filings, press releases, public conference calls and webcasts, we use our website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about our company, our product candidates, our planned financial and other announcements, our attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our LinkedIn page in addition to following our press releases, SEC filings, public conference calls and webcasts.
Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Investor Contact Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]
